Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study

​ Conditions: Gastric Adenocarcinoma; Gastroesophageal Adenocarcinoma; Mismatch Repair Deficient or MSI-High Solid Tumors; Immunotherapy

Interventions: Drug: Adebrelimab; Drug: XELOX; Drug: SHR-8068; Procedure: D2 radical gastrectomy

Sponsors: Shanghai Zhongshan Hospital

Not yet recruiting Conditions: Gastric Adenocarcinoma; Gastroesophageal Adenocarcinoma; Mismatch Repair Deficient or MSI-High Solid Tumors; Immunotherapy
Interventions: Drug: Adebrelimab; Drug: XELOX; Drug: SHR-8068; Procedure: D2 radical gastrectomy
Sponsors: Shanghai Zhongshan Hospital
Not yet recruiting